BioCardia financials
$1.03−0.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.0K | $55.0K | $13.0K | $357.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.0K | $55.0K | $13.0K | $357.0K |
| Gross margin | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$1.6M | -$2.3M | -$2.0M | -$1.5M | -$2.1M | -$2.7M | -$2.3M | -$1.8M | -$1.6M | -$2.3M | -$2.1M | -$2.6M |
| Net income | -$1.6M | -$2.3M | -$2.0M | -$1.5M | -$2.0M | -$2.7M | -$2.3M | -$1.7M | -$1.6M | -$2.3M | -$2.1M | -$2.6M |
| Net margin | — | — | — | — | — | — | — | — | −54866.7% | −4121.8% | −15938.5% | −721.0% |
| Diluted EPS | $-0.13 | $-0.21 | $-0.19 | $-0.24 | $-0.40 | $-0.59 | $-0.50 | $-0.61 | $-0.88 | $-1.35 | $-0.50 | $-1.79 |
| EBITDA | -$1.6M | -$2.3M | -$2.0M | -$1.5M | -$2.0M | -$2.7M | -$2.3M | -$1.7M | -$1.6M | -$2.3M | -$2.1M | -$2.6M |
| Operating cash flow | -$1.7M | -$1.7M | -$2.5M | -$1.7M | -$1.6M | -$1.6M | -$2.4M | -$2.6M | -$1.3M | -$1.5M | -$1.9M | -$2.4M |
| Free cash flow | -$1.7M | -$1.7M | -$2.5M | -$1.7M | -$1.6M | -$1.6M | -$2.4M | -$2.6M | -$1.3M | -$1.5M | -$1.9M | -$2.4M |
| Diluted shares | 12.1M | 10.8M | 10.7M | 6.3M | 5.1M | 4.6M | 4.6M | 2.8M | 1.9M | 1.7M | 4.1M | 1.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.1M | $951.0K | $2.5M | $5.3M | $980.0K | $949.0K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $4.8M | $1.7M | $3.4M | $6.1M | $2.1M | $2.2M |
| Total liabilities | $2.1M | $2.8M | $2.5M | $3.5M | $4.0M | $3.7M |
| Shareholders' equity | $2.7M | -$1.1M | $895.0K | $2.6M | -$1.9M | -$1.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology